Figure 6
From: Safe electrophysiologic profile of dexmedetomidine in different experimental arrhythmia models
(A,B) Cycle-length dependent action potential durations (APD90) and QT interval under baseline conditions (◆), after infusion of 0.5 µM veratridine (■) and after additional treatment with 3 µM dexmedetomidine (▲). (C) Impact of veratridine (Ver) and dexmedetomidine (Dex) on spatial dispersion of repolarization. (D) Occurrence of early afterdepolarizations (EAD) after administration of veratridine and after additional treatment with dexmedetomidine. (E) Incidence of torsade de pointes under baseline conditions, with veratridine and with the combination of veratridine and dexmedetomidine (# = p < 0.05 compared to baseline conditions).
